

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from Zambia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-064070
Article Type:	Original research
Date Submitted by the Author:	25-Apr-2022
Complete List of Authors:	Jamieson, Lise; University of the Witwatersrand Faculty of Health Sciences, Health Economics and Epidemiology Research Office Rosen, Sydney; Boston University School of Public Health, Department of Global Health; Health Economics and Epidemiology Research Office, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand Phiri, Bevis; Clinton Health Access Initiative Grimsrud, Anna; International AIDS Society Mwansa, Muya; Ministry of Health Shakwelele, Hilda; Clinton Health Access Initiative Haimbe, Prudence; Clinton Health Access Initiative Mukumbwa-Mwenechanya, Mpande; Center for Infectious Disease Research in Zambia, Implementation Science Unit Lumano-Mulenga, Priscilla; Ministry of Health Chiboma, Innocent; Ministry of Health Nichols, Brooke ; Health Economics and Epidemiology Research Office; Boston University School of Public Health, Department of Global Health
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, HIV & AIDS < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **How soon should patients be eligible for differentiated service delivery models for antiretroviral**
4 **treatment? Evidence from Zambia**

5
6
7 3 **Short title: Outcomes of early DSD enrolment**

8
9 4 Lise Jamieson^{1,2}, Sydney Rosen^{1,3}, Bevis Phiri⁴, Anna Grimsrud⁵, Muya Mwansa⁶, Hilda Shakwelele⁴,
10
11 5 Prudence Haimbe⁴, Mpande M Mwenechanya⁷, Priscilla Lumano-Mulenga⁶, Innocent Chiboma⁶,
12
13 6 Brooke E Nichols^{1,2,3*}

14
15
16 7
17
18 8 ¹Health Economics and Epidemiology Research Office (HE²RO), Department of Internal Medicine, Faculty of
19
20 9 Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

21
22 10 ²Department of Medical Microbiology, Amsterdam University Medical Centre, Amsterdam, the Netherlands

23
24 11 ³Department of Global Health, Boston University School of Public Health, Boston, MA, USA

25
26 12 ⁴Clinton Health Access Initiative, Lusaka, Zambia

27
28 13 ⁵International AIDS Society, Cape Town, South Africa

29
30 14 ⁶Ministry of Health, Lusaka, Zambia

31
32 15 ⁷The Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

33
34
35 16
36
37 18 *Corresponding author: Brooke Nichols (brooken@bu.edu); Department of Global Health, Boston

38
39 19 University School of Public Health, 801 Massachusetts Avenue, Boston, MA, USA. Tel: +1 857-544-
40
41 20 7250

42
43
44 21
45
46 22 **Keywords:** differentiated service delivery (DSD) models, HIV, antiretroviral treatment, retention in
47
48 23 care, differentiated service delivery guidelines, Zambia

49
50 24
51
52 25 **Word count:**

53
54 26 Abstract: 300/300

55
56 27 Manuscript: 2,719/5,000
57
58
59
60

1
2
3 28 **ABSTRACT**

4 29 **Objectives:** Patient attrition is high the first 6 months after antiretroviral therapy (ART) initiation.
5 30 Patients with <6 months ART are systematically excluded from most differentiated service delivery
6 31 (DSD) models, which are intended to reduce attrition. Despite DSD eligibility criteria requiring ≥ 6
7 32 months on ART, some patients enroll earlier. We compared loss to follow-up (LTFU) between patients
8 33 enrolling in DSD models early to those enrolled according to guidelines, assessing whether the ART
9 34 experience eligibility criterion is necessary.
10 35

11 36 **Setting:** In a retrospective cohort study using routinely-collected electronic medical record data in
12 37 Zambia, we assessed adults (≥ 15 years) who initiated ART between 01/01/2019 and 31/12/2020,
13 38 evaluating LTFU (>30 days late for scheduled visit) at 18 months for “early enrollers” (DSD enrolment
14 39 after <6 months on ART) and “established enrollers” (DSD enrolment after ≥ 6 months on ART). We
15 40 used a log-binomial model to compare LTFU risk, adjusting for age, sex, location, ART refill interval,
16 41 DSD model.
17 42

18 43 **Participants:** For 6,340 early enrollers and 25,857 established enrollers there were no differences in
19 44 sex (61% female), age (median 37 years), or location (65% urban). ART refill intervals were longer for
20 45 established vs early enrollers (72% vs 55% were given 4–6-month refills).
21 46

22 47 **Results:** LTFU at 18 months was 3% (192/6,340) for early enrollers and 5% (24,646/25,857) for
23 48 established enrollers. Early enrollers were 41% less likely to be LTFU than established patients
24 49 (adjusted risk ratio [95% confidence interval] 0.59 [0.50-0.68]).
25 50

26 51 **Conclusions:** Patients enrolled in DSD after <6 months’ ART were more likely to be retained than
27 52 patients established on ART prior to DSD enrolment. A limitation is that early enrollers may have been
28 53 selected for DSD due to providers’ and patients’ expectations about future retention. Offering DSD
29 54 models to at least some ART patients soon after ART initiation may help address high attrition during
30 55 the early treatment period.
31 56
32 57
33 58
34 59
35 60

1
2
3 56 **KEY QUESTIONS**
4

5 57 **What is already known on this topic**

- 6 58 • Differentiated service delivery (DSD) for HIV treatment can increase access and remove
7 barriers to care.
8 59
9 60 • DSD models are generally designed for patients who are established in care, having at least 6
10 61 months of treatment before being eligible for DSD model enrolment.
11 62 • Studies have shown that patients in DSD treatment models in sub-Saharan Africa (SSA) have
12 63 a similar retention in care (generally within 5%), compared to patients who access treatment in
13 64 conventional, facility-based care.

14
15
16
17
18
19 65 **What this study adds**

- 20
21 66 • Limited data exists on patient outcomes of those who enrol in DSD models early, i.e. patients
22 67 with <6 months of HIV treatment.
23 68 • We show that patients in Zambia who enrolled into DSD models, designed for established
24 69 patients, early were significantly less likely to be lost to follow-up compared to patients who
25 70 enrolled into DSD models as per guideline criteria.

26
27
28
29
30
31 71 **How this study might affect research, practice or policy**

- 32
33 72 • This analysis provides a critical first step towards the reassessment of the delayed DSD
34 73 enrolment policies.
35 74 • This work signals that further research needs to be conducted in other SSA countries to
36 75 evaluate patient outcomes for early DSD model enrolment.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

76 INTRODUCTION

77 A critical step toward achieving universal coverage of antiretroviral therapy (ART) for HIV is to support
78 lifelong patient retention in ART programmes. Data from sub-Saharan Africa (SSA), where some 70%
79 of the world's ART patients reside, continue to indicate insufficient retention on ART,¹ with about a
80 fifth of all patients lost to care five years after treatment initiation.² A patient's first six months after
81 initiation are a high risk period for attrition: a Zambian study showed rates of loss to follow-up to be
82 four-fold higher in the first six months of ART treatment compared to the period between six months
83 and 3.5 years thereafter.³

84
85 Since 2016, the World Health Organization (WHO) has recommended differentiated service delivery
86 (DSD) for HIV treatment.⁴ DSD models such as facility-based individual "fast track" medication pickup
87 and community-based ART refills can increase access and remove barriers to care by adjusting the
88 cadre of provider, location of service delivery, frequency of interactions with the healthcare system,
89 and/or types of services offered to support long-term retention of people established on HIV treatment.⁵
90 A recent systematic review reporting on outcomes of patients in DSD models in SSA found that
91 retention in care of those in DSD models was generally within 5% of that for conventional care.⁶ In
92 Zambia, several DSD models have shown to have similar rates of retention as conventional care 12
93 months after DSD model entry.^{7,8} The INTERVAL trial, a cluster-randomized, non-inferiority trial
94 conducted in Malawi and Zambia, found that 6-month ART dispensing was non-inferior in terms of 12-
95 month retention, compared to standard of care.⁸ DSD models have consistently been found to save
96 substantial time and money for patients themselves, and satisfaction with the models among both
97 providers and patients has been high.⁸⁻¹⁰

98
99 A major limitation of DSD models to date has been eligibility criteria that limit model enrollment to
100 patients on the standard first-line ART regimen who are "stable" or "established on treatment," defined
101 as having been on ART for at least 6 or 12 months and having documented viral suppression.^{8,11-13} Until
102 April 2021, the WHO's definition of "established" included at least 12 months of ART experience; new
103 guidelines require at least 6 months on ART for DSD model eligibility¹⁴. Patients who are newly

1
2
3 104 initiated on ART are thus systematically excluded from stable-patient-specific DSD models and from
4
5 105 the benefits they offer. In the previously cited INTERVAL trial in Malawi and Zambia, 10% of all
6
7 106 patients were excluded due to having initiated ART less than 6 months prior.¹⁵ For patients not eligible
8
9 107 for DSD models, guidelines typically require frequent visits to the healthcare facility and medication
10
11 108 dispensing intervals of no more than 3 months.¹⁶ In Zambia, all care is differentiated and dependent on
12
13 109 the needs of the patient,¹¹ but currently there is no evidence on the outcomes of patients with <6 months
14
15 110 ART experience who enroll into DSD models that are typically reserved for stable patients.

16
17
18 111
19
20 112 Despite existing guidelines limiting DSD eligibility based on time on ART, in practice patients who do
21
22 113 not meet guideline-recommended criteria are sometimes enrolled in DSD models for stable patients,
23
24 114 due to provider decision, error or patient request. To begin to understand how such patients who are
25
26 115 referred early to DSD models fare when participating in DSD models designed for those established on
27
28 116 treatment, we analyzed routinely collected medical record data from Zambia to compare rates of
29
30 117 retention among patients enrolled into DSD models earlier than guidelines recommend with retention
31
32 118 among those who met all eligibility criteria.

33 34 35 119 36 37 120 **METHODS**

38 39 121 **Study population and outcomes**

40
41
42 122 We conducted a retrospective cohort study with data extracted in October 2021 from SmartCare,
43
44 123 Zambia's national electronic medical record system.¹⁷ We extracted data for patients, aged 15 years or
45
46 124 older, reported to have initiated ART between January 2019 and December 2020 at any of 692 health
47
48 125 facilities across all 10 provinces. Zambian policy guidelines for this period required patients to be stable
49
50 126 on ART before they are considered for DSD enrolment, with stability defined in the 2018 consolidated
51
52 127 ART guidelines^{11,12} as on ART for at least six months.

53
54 128
55
56 129 We defined patients who enrolled into a DSD model with <6 months of ART as “early enrollers”, while
57
58 130 a comparison group of patients who enrolled into a DSD model with ≥ 6 months of ART as “established
59
60

131 enrollers”. Patients on second-line ART (defined as those dispensed protease inhibitors such as
 132 lopinavir, atazanavir or ritonavir) were excluded from this analysis, as they are already known to be at
 133 high risk of attrition.^{18,19} For both early and established enrollers, we assessed loss to follow-up (LTFU)
 134 at 18 months post-ART initiation, with LTFU defined as patients who were reported as “lost to follow-
 135 up” or “inactive” in the SmartCare database between 15 and 21 months after ART initiation date.
 136 “Inactive” was defined as having missed a scheduled visit by more than 30 days. Rates of LTFU were
 137 calculated for early and established enrollers and stratified by DSD model type and ART dispensing
 138 duration. DSD models, which had multiple names in the SmartCare database, were grouped into the
 139 following categories: 1) adherence groups (community adherence groups, rural/urban adherence
 140 groups); 2) extended clinic hours (DSD models designed for clinic access before/after hours or
 141 weekends, including scholar models); 3) fast-track (procedures to accelerate dispensing at clinics); 4)
 142 home ART delivery; 5) multi-month dispensing (MMD); and 6) community pick-up point (central
 143 dispensing units, community retail pharmacies, community ART distribution points, health posts,
 144 mobile ART distribution models) (Table 1).

146 **Table 1. Differentiated service delivery (DSD) models for HIV treatment in use in Zambia**
 147 **during the study period**

Category	Model(s) in category	Description
Adherence groups	Community adherence groups	Patient groups, consisting of ±6 members, meeting at an agreed time every 1-3 months. The groups are managed by the patients themselves, and usually meet outside of the health facility. Members collect ART at clinical appointments for other members in a rotating fashion. ⁷
	Rural and urban adherence groups/clubs	Patient groups, consisting of 20-30 members, meeting at an agreed time every 2-3 months. Groups are often facilitated by the same health care worker or facility-based volunteer, also providing pre-packaged ART. ⁷
Community pick-up point	Central dispensing units	A centralized model for ART distribution, where medication is packed at a centrally located hub and distributed to patients at multiple approved pick-up points. Clinic visits occur every 6 months at the health facility. ¹¹

Category	Model(s) in category	Description
	Community ART distribution points, community retail pharmacies, health posts	ART refills are provided to patients outside of health facilities, e.g. schools, churches, community centres, community retail pharmacies and health posts. ¹¹
	Mobile ART distribution models	A clinical outreach team linked to a facility does 3-monthly clinical assessments at community distribution points. This model is usually used for hard-to-reach areas. ¹¹
Extended clinic hours	Before/after-hours models, weekend models, scholar models	These models allow patients to have a clinical visit and collect their ART outside the conventional operation times at the facility (early mornings, evenings and over weekends). These are beneficial to patients with competing priorities (e.g. school or employment).
Fast-track	Fast-track	A model that typically involves a separate, shorter queue to dispense ART to stable patients, allowing for a quick patient visit when a clinical visit is not required. ²⁰
Home ART delivery	Home ART delivery	Trained community health workers (CHWs) linked to facilities conduct home visits to deliver ART, conduct health screening, monitor adherence, and refer patients as required. ⁷
Multi-month dispensing	Multi-month dispensing	Facility-based model in which the primary goal is to dispense medications for more than one month (usually 6 months). Dispensing is typically done during a clinical facility-based visit.

148

149 Statistical analysis

150 We described the demographics of our study population using descriptive statistics. We compared loss
 151 to follow-up risk between early enrollers and established enrollers and Wilson's score interval was used
 152 to calculate 95% confidence intervals around proportions. We used a log-binomial regression to
 153 calculate risk ratios for loss to follow-up, adjusting for age, sex, urban/rural status, DSD model type
 154 and ART dispensing duration. Analyses were also stratified by DSD model type and ART dispensing
 155 duration. Further, we also conducted an age-stratified analysis and a sub-analysis restricted to facilities
 156 with a higher proportion of early enrollers, with results shown in the supplementary material.

157

158 Patient and public involvement

159 Patients and the public were not involved in the design and conduct of this research.

160

161 RESULTS

162 Study populations

163 The full SmartCare data set included 1,520,125 unique patients on ART over 2018-2021, of which
 164 32,197 patients had enrolled into a DSD model after ART initiation and had an 18-month outcome
 165 reported within the 15-to-21-month window (Figure 1). Of these, 6,340 patients were reported to have
 166 been enrolled in DSD models <6 months after ART initiation during the study period (early enrollers).
 167 The remaining 25,857 patients comprised the comparison group of established enrollers. For early
 168 enrollers, median time enrolled in a DSD model at the time of outcome evaluation was 14.7 months
 169 (IQR 13.0-16.5); majority (81%, n=20,856) of established enrollers were on DSD models at outcome
 170 evaluation at a median of 5.8 months (interquartile range (IQR) 2.9-8.9) (Table 2). Early enrollers and
 171 established enrollers were similar with respect to age, sex and urban/rural location. Across both groups,
 172 the median age was 37 years (IQR 29 – 44), a majority (61%, 19,580/32,197) were female and most
 173 patients resided in urban settings (64%, n=20,618).

174 **Table 2. Demographics of patients enrolled in differentiated service delivery models**

Variable	Early enrollers of DSD models (N=6,340)	Established enrollers of DSD models (N=25,857)
Age in years, median (IQR)	36 (29-44)	37 (29-44)
Age group	15-24	2,589 (10%)
	25-34	8,346 (32%)
	35-49	11,424 (44%)
	50+	3,487 (13%)
Sex	Female	15,666 (61%)
	Male	10,191 (39%)
Location	Rural	9,078 (35%)
	Urban	16,779 (65%)
Year of ART initiation	2019	17,346 (67%)
	2020	8,511 (33%)
DSD type	Adherence groups	508 (2%)
	Community pickup points	1,461 (6%)
	Extended clinic hours	97 (<1%)
	Fast-track	6,266 (24%)

Variable	Early enrollers of DSD models (N=6,340)	Established enrollers of DSD models (N=25,857)
Home ART delivery	355 (6%)	973 (4%)
Multi-month dispensing	4,101 (65%)	16,552 (64%)
ART months dispensed		
<2 months	636 (10%)	1,476 (6%)
3 months	2,197 (35%)	5,688 (22%)
4-6 months	3,507 (55%)	18,679 (72%)
Outcome Year		
2020	2,863 (45%)	17,283 (67%)
2021	3,477 (55%)	8,574 (33%)
Months on ART at outcome, median (IQR)	17.9 (16.4-19.5)	18.4 (16.7-19.8)
On DSD at outcome		
Yes	6,340 (100%)	20,856 (81%)
No	0 (0%)	5,001 (19%)
Months on DSD at outcome, median (IQR)	14.7 (13.0-16.5)	5.8 (2.9-8.9)
Patient outcomes by 18 months after ART initiation		
On treatment	6,133 (97%)	24,646 (95%)
Died	11 (<1%)	31 (<1%)
Lost to follow-up	192 (3%)	1,169 (5%)
Stopped ART	4 (<1%)	10 (<1%)
Stopped DSD	0 (0%)	1 (<1%)

175

176 Most patients were enrolled in either multi-month dispensing DSD models (65% [n=4,101] of early
 177 enrollers and 64% [n=16,552] of established enrollers) or fast-track (15% [n=979] of early enrollers
 178 and 24% [n=6,266] of established enrollers) (Table 1). Amongst early enrollers, around half (55%,
 179 n=3,477) were dispensed 4-6 months of ART at their most recent ART pickup, 35% (n=2,197) were
 180 dispensed 3 months of ART, and 10% (n=636) were dispensed <2 months of ART. Established enrollers
 181 had slightly longer dispensing intervals with 72% (n=18,679) dispensed 4-6 months of ART, 22%
 182 (n=5,688) dispensed 3 months of ART, and 6% (n=1,476) dispensed <2 months of ART (Table 1).

183

184 Outcomes

185 Early enrollers had a slightly lower rate of loss to follow-up (3.0% [95% confidence interval (CI) 2.6%-
 186 3.5%]) compared to the established enrollers (4.5% [4.3%-4.8%]) (Table 3). Early enrollers experienced
 187 similar or lower loss to follow-up rates than established enrollers across nearly all differentiated models
 188 of care. The exception was extended clinic hours: early enrollers enrolled in the extended clinic hours
 189 model had a similar rate of loss to follow-up than established enrollers (10.6%; [5.7%-18.9%] vs. 8.2%
 190 [4.2%-15.4%], respectively). Across both early and established enrollers, longer dispensing periods
 191 were associated with lower rates of loss to follow-up, which increased from 2.5%-3.8% for 4-6-month

192 dispensing to 3.5%-5.3% for 3-month dispensing to 4.1%-10.6% for <2-month dispensing (Table 3).
 193 Early enrollers with <2 months dispensing had a lower rate of loss to follow-up than did established
 194 enrollers (4.1%; [2.8%-5.9%] vs. 10.6% [9.1%-12.2%]).

195

196 **Table 3. Relative risk of loss to follow-up at 18 months post-ART initiation for early enrollers of**
 197 **differentiated service delivery (DSD) models**

	Proportion of patients lost to follow-up at 18 months, % (95% CI) [n/N]		Unadjusted risk ratio (95% CI)	Adjusted risk ratio* (95% CI)
	Early enrollers	Established enrollers		
All patients	3.0% (2.6% - 3.5%) [192/6,340]	4.5% (4.3% - 4.8%) [1,169/25,857]	0.67 (0.57-0.78)	0.59 (0.50-0.68)
Stratification: DSD model				
Adherence groups	2.7% (1% - 6.7%) [4/149]	3.1% (1.9% - 5.1%) [16/508]	0.85 (0.25-2.29)	0.79 (0.23-2.12)
Community pickup points	4.5% (3.1% - 6.3%) [30/671]	3.3% (2.5% - 4.3%) [48/1,461]	1.36 (0.86-2.12)	1.30 (0.81-2.03)
Extended clinic hours	10.6% (5.7% - 18.9%) [9/85]	8.2% (4.2% - 15.4%) [8/97]	1.28 (0.51-3.27)	1.19 (0.43-3.34)
Fast track	3.4% (2.4% - 4.7%) [33/979]	3.6% (3.2% - 4.1%) [227/6,266]	0.93 (0.64-1.31)	0.74 (0.50-1.05)
Home ART delivery	1.4% (0.6% - 3.3%) [5/355]	6.3% (4.9% - 8%) [61/973]	0.22 (0.08-0.50)	0.18 (0.06-0.41)
Multi-month dispensing	2.7% (2.3% - 3.2%) [111/4,101]	4.9% (4.6% - 5.2%) [809/16,552]	0.55 (0.45-0.67)	0.51 (0.41-0.61)
Stratification: ART dispensing duration				
<2 months	4.1% (2.8% - 5.9%) [26/636]	10.6% (9.1% - 12.2%) [156/1,476]	0.39 (0.25-0.57)	0.40 (0.26-0.59)
3 months	3.5% (2.8% - 4.4%) [77/2,197]	5.3% (4.8% - 5.9%) [303/5,688]	0.66 (0.51-0.84)	0.64 (0.49-0.81)
4-6 months	2.5% (2.1% - 3.1%) [89/3,507]	3.8% (3.5% - 4.1%) [709/18,679]	0.67 (0.54-0.83)	0.67 (0.53-0.82)

198 *Model adjusted for age, sex, location, ART dispensing duration and DSD model type

199

200 In an analysis adjusting for age, sex, location, ART dispensing duration, and DSD model type, early
 201 enrollers in all DSD model types and dispensing durations were 41% less likely to be lost to follow-up
 202 than established enrollers (adjusted risk ratio (aRR) 0.59 [0.50-0.68]) (Table 3). The reduced adjusted
 203 risk of being lost to follow-up were similar for patients in adherence groups (aRR 0.79 [0.23-2.12]),
 204 multi-month dispensing (aRR 0.51 [0.41-0.61]), home ART delivery (aRR 0.18 [0.06-0.41]) and fast
 205 track models (aRR 0.74 [0.50-1.05]). Early enrollers had a statistically insignificant increased risk of
 206 being lost to follow-up in the community pick-up point (aRR 1.30 [0.81-2.03]) and extended clinic
 207 hours models (aRR 1.19 [0.43-3.34]) compared to the established enrollers.

208

1
2
3 209 An age-stratified analysis produced similar results to the main analysis, with early enrollers in each age
4
5 210 group being less likely to be lost to follow-up than established enrollers in the same age group. However,
6
7 211 the effect of earlier enrollment in DSD on reduced loss to follow-up appeared less pronounced in
8
9 212 patients on 4-6 months' ART dispensing for those aged 25 to 49 years (Appendix Figure S1). In
10
11 213 facilities where a larger proportion of all DSD patients enrolled in DSD models early, the trend towards
12
13 214 early enrollers performing better persisted with respect to loss to follow-up compared to outcomes for
14
15 215 established enrollers (Appendix Figure S2).
16
17
18 216
19

20 217 **DISCUSSION**

21
22 218 In nearly all of sub-Saharan Africa, DSD model eligibility criteria require that patients be on ART for
23
24 219 a minimum of six months (and in some countries a minimum of 12 months) prior to DSD model
25
26 220 enrollment.²¹ We present novel data from Zambia highlighting good outcomes when newly initiated
27
28 221 ART patients (those with less than 6 months' ART experience) are referred early to DSD models. Those
29
30 222 referred early to DSD appear to have good outcomes across different DSD models and age categories.
31
32

33 223
34
35 224 Our data begin to fill in a gap in the evidence base on the validity of time on treatment as an eligibility
36
37 225 criterion for DSD models. Because few if any countries permit DSD model enrollment for new
38
39 226 initiators, little evidence on their experience in DSD models has been available until now. To date, most
40
41 227 reports on DSD outcomes have been limited to people who have spent a significant amount of time on
42
43 228 ART prior to DSD model enrollment. In the previously mentioned INTERVAL trial, for example,
44
45 229 participants had been on ART for a median of roughly five years at DSD model entry, while patients in
46
47 230 a trial of multi-month dispensing in adherence clubs in South Africa had a median duration on ART of
48
49 231 7.3 years at baseline.²²
50

51 232
52
53 233 While ART patients in Zambia have historically been lost to follow-up at high rates in the first few
54
55 234 months after ART initiation,³ in our DSD patient population this was less likely to be the case. Our
56
57 235 results provide evidence to support the recent revision of WHO guidelines that reduce time on ART
58
59 236 from 12 to six months on treatment as part the definition of "established" on ART.¹⁴ These findings
60

1
2
3 237 offer reassurance and evidence to countries that have expanded eligibility as they scale up DSD
4
5 238 models,^{21,23} particularly to support uninterrupted access to HIV treatment during the COVID-19
6
7 239 pandemic, that earlier referral to DSD is possible without compromising patient care. Even if many, or
8
9 240 most, of the patients in our “early enrollment” sample were selected deliberately because they were
10
11 241 considered at low loss to follow-up risk, our results demonstrate that early eligibility for DSD models
12
13 242 should be considered for at least some patients before they reach six months on ART.
14

15
16 243
17
18 244 Loss to follow up at 18 months after ART initiation for early and established enrollers averaged 1-11%
19
20 245 for all six categories of DSD models studied. We did not observe any programmatically important
21
22 246 differences by model or ART experience prior to model enrollment. Where a programmatically
23
24 247 important difference did arise, in contrast, was in dispensing intervals. Regardless of how long a patient
25
26 248 had been on ART at DSD model enrollment, patients who received ≤ 2 months of medications at a time
27
28 249 were more likely to be lost to follow up than patients who received either 3 months or 4-6 months of
29
30 250 medications. This likely reflects providers’ assessments of patients’ ability to remain on treatment
31
32 251 and/or clinical condition. Those regarded as being at higher risk of attrition are asked to come to the
33
34 252 clinic for medication refills more often, so that they can be monitored and supported more closely.
35
36 253 Ironically, difficulty in accessing the clinic may be the very reason that some patients are at high risk
37
38 254 of attrition. For these patients, insisting on shorter refill durations may simply exacerbate whatever
39
40 255 challenges they face.
41

42
43 256
44
45 257 There were several limitations to our analysis. First, as noted above, we assume that patients with <6
46
47 258 months on ART in our sample were not offered DSD model enrollment at random. If providers made
48
49 259 accurate clinical decisions about individual patients’ risks of attrition, patients in our “early enrollment”
50
51 260 cohorts could over-represent patients thought to have low attrition risk. To achieve the results we found,
52
53 261 providers would have had to make these decisions correctly at multiple sites across the entire country.
54
55 262 If this is the case, our data suggest that the healthcare workers responsible for enrolling patients into
56
57 263 DSD models can successfully identify those who will do well with early enrollment. At the same time,
58
59 264 if the early enrollers in our data set do comprise patients at lower risk of loss to follow-up, then our
60

1
2
3 265 results likely underestimate the true rate of loss to follow-up that would occur if early DSD enrollment
4
5 266 were to be broadly available, without the benefit of provider selection.
6

7 267
8

9 268 A second limitation is that our data set included only patients reported in the electronic medical record
10
11 269 system to have enrolled in a DSD model. It is possible that some patients not in DSD models may be
12
13 270 recorded as enrolled, and some who were enrolled may have been missed. Third, bias could occur if
14
15 271 facilities with better-than-average retention in care were also more likely to allow early DSD model
16
17 272 enrollment. In this case, our results may reflect differences in facility quality, as well as enrollment
18
19 273 timing. An analysis restricted to facilities with >20% early DSD enrolment showed an even lower risk
20
21 274 of loss to follow-up among patients enrolled early into DSD models, however, compared to patients
22
23 275 with >6 months of ART at DSD entry.
24
25

26 276
27

28 277 Despite these limitations, our analysis demonstrates that patients on ART for less than six months who
29
30 278 are enrolled in existing DSD models can be successfully retained in care and may even fare better than
31
32 279 those left in conventional care and only initiate DSD models greater than six months after ART
33
34 280 initiation. It is likely that not all patients are ready for less intensive DSD models in their first half-year
35
36 281 or year on treatment, but some clearly are. Since DSD models have been shown to be beneficial to
37
38 282 patients and in some cases to providers, offering enrollment to newly-initiating ART patients may
39
40 283 improve ART programs in general. Future research should look more closely at which patients can be
41
42 284 enrolled early and which models of care serve these patients best.
43
44

45 285
46

47 286 **CONCLUSION**

48
49 287 Current policy for DSD model eligibility criteria in Zambia, as in other countries, have required a
50
51 288 minimum of 12 months of ART before a patient is considered for DSD enrolment, and more recently,
52
53 289 a minimum of six months of ART. In order to change guidelines to allow DSD enrolment sooner after
54
55 290 ART initiation (i.e., 6 months or less), large-scale observational evidence, implementation research or
56
57 291 trial data demonstrating good patient outcomes among those who enrol in DSD models < six months'
58
59 292 post ART initiation would be required. This analysis therefore provides a critical first step towards the
60

1
2
3 293 reassessment of the delayed DSD enrolment policies, and signals that further research needs to be
4
5 294 conducted in other SSA countries to evaluate patient outcomes for early DSD model enrolment.
6
7

8 295 **COMPETING INTERESTS**

9
10 296 We declare no competing interests.
11
12

13 297 **AUTHORS' CONTRIBUTIONS**

14
15
16 298 LJ, BN, SR and AG conceptualized the study. BP, HS, PH, MM, PLM, IC curated data for the study.
17
18 299 BP, HS, PH, MMM provided supervision of the study. LJ led data analysis and drafted the paper along
19
20 300 with BN, SR and AG. All authors contributed to data interpretation and critically reviewed a revised
21
22 301 draft of the manuscript. All authors have read and approved the final manuscript.
23
24

25 302 **FUNDING**

26
27
28 303 Funding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to
29
30 304 Boston University. The funder had no role in study design, data collection and analysis, decision to
31
32 305 publish or preparation of the manuscript.
33
34

35 306 **DATA SHARING**

36
37
38 307 The data is owned by the Zambian Ministry of Health and the use of it was approved by the Human
39
40 308 Research Ethics Committee (University of Witwatersrand, Johannesburg, South Africa) and ERES
41
42 309 Converge IRB (Zambia). All relevant data is included in the paper and supplementary material. The full
43
44 310 data are available upon approval from Zambian Ministry of Health and appropriate ethics committees.
45
46

47 311 **ETHICS**

48
49 312 This study protocol was approved by ERES Converge IRB (Zambia), protocol number 2019-Sep-030,
50
51 313 the Human Research Ethics Committee (Medical) of the University of Witwatersrand, protocol number
52
53 314 M190453, and the Boston University IRB H-38823 for the use of data with a waiver of consent.
54
55

56 315
57


58 316
59
60

317 REFERENCES

- 318 1. *UNAIDS AIDSinfo: People Living with HIV Receiving ART.*; 2020. Accessed June 15, 2021.
319 <https://aidsinfo.unaids.org/>
- 320 2. Haas AD, Zaniewski E, Anderegg N, et al. Retention and mortality on antiretroviral therapy in
321 sub-Saharan Africa: collaborative analyses of HIV treatment programmes. *J Intern AIDS Soc.*
322 2018;21(2):e25084. doi:10.1002/jia2.25084
- 323 3. Schöni-Affolter F, Keiser O, Mwangi A, et al. Estimating Loss to Follow-Up in HIV-Infected
324 Patients on Antiretroviral Therapy: The Effect of the Competing Risk of Death in Zambia and
325 Switzerland. Myer L, ed. *PLoS ONE.* 2011;6(12):e27919. doi:10.1371/journal.pone.0027919
- 326 4. *World Health Organization. Guidelines on HIV Self-Testing and Partner Notification,*
327 *Supplement to Consolidated Guidelines on HIV Testing Services.*; 2016. Accessed November
328 18, 2020. <https://www.who.int/hiv/pub/vct/hiv-self-testing-guidelines/en/>
- 329 5. Duncombe C, Rosenblum S, Hellmann N, et al. Reframing HIV care: putting people at the
330 centre of antiretroviral delivery. *Trop Med Int Health.* 2015;20(4):430-447.
331 doi:10.1111/tmi.12460
- 332 6. Long L, Kuchukhidze S, Pascoe S, et al. Retention in care and viral suppression in differentiated
333 service delivery models for HIV treatment delivery in sub-Saharan Africa: a rapid systematic
334 review. *J Intern AIDS Soc.* 2020;23(11). doi:10.1002/jia2.25640
- 335 7. Nichols BE, Cele R, Jamieson L, et al. Community-based delivery of HIV treatment in Zambia:
336 costs and outcomes. *AIDS.* 2021;35(2):299-306. doi:10.1097/QAD.0000000000002737
- 337 8. Hoffman RM, Moyo C, Balakasi KT, et al. Multimonth dispensing of up to 6 months of
338 antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded,
339 non-inferiority trial. *The Lancet Global Health.* 2021;9(5):e628-e638. doi:10.1016/S2214-
340 109X(21)00039-5
- 341 9. Nichols BE, Cele R, Lekodeba N, et al. Economic evaluation of differentiated service delivery
342 models for HIV treatment in Lesotho: costs to providers and patients. *J Intern AIDS Soc.*
343 2021;24(4). doi:10.1002/jia2.25692
- 344 10. Guthrie T, Muheki C, Greener R, et al. *Costs and Outcomes of Differentiated ART Service*
345 *Delivery in Uganda: Summary of Findings.*; 2020.
346 [https://sites.bu.edu/ambit/files/2021/02/Uganda-EQUIP-Brief-ART-DSDM-cost-outcomes-](https://sites.bu.edu/ambit/files/2021/02/Uganda-EQUIP-Brief-ART-DSDM-cost-outcomes-FINAL-2020.08.24.pdf)
347 [FINAL-2020.08.24.pdf](https://sites.bu.edu/ambit/files/2021/02/Uganda-EQUIP-Brief-ART-DSDM-cost-outcomes-FINAL-2020.08.24.pdf)
- 348 11. *Ministry of Health. Zambia Differentiated Service Delivery Framework.*; 2018.
- 349 12. *Republic of Zambia. Ministry of Health. Zambia Consolidated Guidelines for Treatment and*
350 *Prevention of HIV Infection.*; 2018.
- 351 13. *Republic of Zambia. Ministry of Health. Zambia Consolidated Guidelines for Treatment and*
352 *Prevention of HIV Infection.*; 2020.
- 353 14. *World Health Organization. Updated Recommendations on Service Delivery for the Treatment*
354 *and Care of People Living with HIV.*; 2021.
355 <https://apps.who.int/iris/rest/bitstreams/1344311/retrieve>

- 1
2
3 356 15. Hoffman RM, Balakasi K, Bardon AR, et al. Eligibility for differentiated models of HIV
4 357 treatment service delivery: an estimate from Malawi and Zambia. *AIDS*. 2020;34(3):475-479.
5 358 doi:10.1097/QAD.0000000000002435
6
7 359 16. Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a
8 360 patient's first six months on antiretroviral therapy for HIV: an applied research agenda. *Gates*
9 361 *Open Res*. 2020;4:116. doi:10.12688/gatesopenres.13159.1
10
11 362 17. Gumede-Moyo S, Todd J, Bond V, Mee P, Filteau S. A qualitative inquiry into implementing an
12 363 electronic health record system (SmartCare) for prevention of mother-to-child transmission data
13 364 in Zambia: a retrospective study. *BMJ Open*. 2019;9(9):e030428. doi:10.1136/bmjopen-2019-
14 365 030428
15
16 366 18. Wandeler G, Keiser O, Mulenga L, et al. Tenofovir in Second-Line ART in Zambia and South
17 367 Africa: Collaborative Analysis of Cohort Studies. *JAIDS Journal of Acquired Immune*
18 368 *Deficiency Syndromes*. 2012;61(1):41-48. doi:10.1097/QAI.0b013e3182632540
19
20 369 19. Kebede HK, Mwanri L, Ward P, Gesesew HA. Predictors of lost to follow up from antiretroviral
21 370 therapy among adults in sub-Saharan Africa: a systematic review and meta-analysis. *Infect Dis*
22 371 *Poverty*. 2021;10(1):33. doi:10.1186/s40249-021-00822-7
23
24 372 20. Huber A, Pascoe S, Nichols B, et al. Differentiated Service Delivery Models for HIV Treatment
25 373 in Malawi, South Africa, and Zambia: A Landscape Analysis. *Glob Health Sci Pract*. Published
26 374 online May 10, 2021;ghsp;GHSP-D-20-00532v1. doi:10.9745/GHSP-D-20-00532
27
28 375 21. *Time on ART before Eligibility for DSD for HIV Treatment. Differentiated Service Delivery*.
29 376 International AIDS Society (IAS); 2020.
30 377 [https://differentiatedservicedelivery.org/Portals/0/adam/Content/jcdklT8RzEqirRdlckAjbQ/File/](https://differentiatedservicedelivery.org/Portals/0/adam/Content/jcdklT8RzEqirRdlckAjbQ/File/1-Time%20to%20DSD%20Eligibility%20D5.pdf)
31 378 [1-Time%20to%20DSD%20Eligibility%20D5.pdf](https://differentiatedservicedelivery.org/Portals/0/adam/Content/jcdklT8RzEqirRdlckAjbQ/File/1-Time%20to%20DSD%20Eligibility%20D5.pdf)
32
33 379 22. Cassidy T, Grimsrud A, Keene C, et al. Twenty-four-month outcomes from a cluster-
34 380 randomized controlled trial of extending antiretroviral therapy refills in ART adherence clubs. *J*
35 381 *Int AIDS Soc*. 2020;23(12):e25649. doi:10.1002/jia2.25649
36
37 382 23. Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV treatment in
38 383 sub-Saharan Africa during COVID-19. *J Int AIDS Soc*. 2021;24(6). doi:10.1002/jia2.25704
39
40 384
41
42 385
43
44 386
45
46
47
48
49
50

51 387 **Figure 1: Flow diagram depicting study population**
52
53
54
55
56
57
58
59
60



Flow diagram depicting study population

157x99mm (300 x 300 DPI)

Supplementary Appendix to:

How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment?

Lise Jamieson^{1,2*}, Sydney Rosen^{1,3}, Bevis Phiri⁴, Anna Grimsrud⁵, Muya Mwansa⁶, Hilda Shakwelele⁴, Prudence Haimbe⁴, Mpande M Mwenechanya⁷, Priscilla Lumano Mulenga⁶, Innocent Chiboma⁶, Brooke E Nichols^{1,2,3*}

¹Health Economics and Epidemiology Research Office (HE²RO), Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ²Department of Medical Microbiology, Amsterdam University Medical Centre, Amsterdam, the Netherlands; ³Department of Global Health, Boston University School of Public Health, Boston, MA, USA; ⁴Clinton Health Access Initiative, Lusaka, Zambia; ⁵International AIDS Society, Cape Town, South Africa; ⁶Ministry of Health, Lusaka, Zambia ⁷The Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

Figure S1. Relative risk of loss to follow-up within 18 months of ART initiation for early enrollers of DSD models (ie. after <6 months of ART), stratified by dispensing period and age group (reference group: established enrollers of DSD models with >6 months of ART at DSD enrolment; analysis adjusted for sex and urban/rural status)





Figure S2. Proportion loss to follow-up by time on ART at DSD entry, limited to N=37 facilities with >20% of DSD patients at each facility classified as “early enrollers”



A potential area of concern was that facilities that had better-than-average retention would be more willing or able to enroll patients into DSD models early and therefore skew the results. We therefore conducted this sub-analysis where we limited the data to those facilities which had substantial proportion of their patients enrolled into DSD models early. Criteria for this analysis limited the data to facilities where: i) $\geq 20\%$ of patients had early enrollers, and ii) at least 100 patients across both groups (early enrollers and established enrollers). 37 facilities across 8 of 10 provinces were selected for this analysis; 73% (n=27) of facilities were in urban areas. This analysis consisted of 7,103 patients: majority (61%, n=4,351) were female, age group distribution was similar to the main analysis (Table 2) (11%, n=784 were 15-24 years; 35%, n=2,488 were 25-34 years; 43%, n=3,028 were 35-49 years; 11%, n=799 were 50+ years), 81% (n=5,731) of patients were in urban settings. Majority (57%, n=4,028) of patients were enrolled into multi-month dispensing, 29% (n=2,058) were in fast-track, 7% (n=484) were in community pick-up points, 5% (n=350) were in home ART delivery, and <2% were in adherence groups (n=112) and extended clinic hours' groups (n=71).

Results show that in this subset of clinics, early enrollers were less likely to be lost to follow-up (3.0% [77/2,543]), compared to established enrollers (4.6% [212/4,560]). A log-binomial regression assessing risk of loss to follow-up, adjusting for age, sex, urban/rural status, and ART dispensing period estimated that, compared to established enrollers, early enrollers were 40% less likely to be lost to follow-up; adjusted risk ratios (aRR) 0.60 (95% CI 0.46-0.78).

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8, Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	8-9, Table 2
Outcome data	15*	Report numbers of outcome events or summary measures over time	9-10

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
10				
11	Discussion			
12				
13	Key results	18	Summarise key results with reference to study objectives	11
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-13
15				
16	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-13
17				
18				
19	Generalisability	21	Discuss the generalisability (external validity) of the study results	13-14
20				
21	Other information			
22				
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14
24				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from a retrospective cohort study in Zambia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-064070.R1
Article Type:	Original research
Date Submitted by the Author:	03-Nov-2022
Complete List of Authors:	Jamieson, Lise; University of the Witwatersrand Faculty of Health Sciences, Health Economics and Epidemiology Research Office Rosen, Sydney; Boston University School of Public Health, Department of Global Health; Health Economics and Epidemiology Research Office, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand Phiri, Bevis; Clinton Health Access Initiative Grimsrud, Anna; International AIDS Society Mwansa, Muya; Ministry of Health Shakwelele, Hilda; Clinton Health Access Initiative Haimbe, Prudence; Clinton Health Access Initiative Mukumbwa-Mwenechanya, Mpande; Center for Infectious Disease Research in Zambia, Implementation Science Unit Lumano-Mulenga, Priscilla; Ministry of Health Chiboma, Innocent; Ministry of Health Nichols, Brooke ; Health Economics and Epidemiology Research Office; Boston University School of Public Health, Department of Global Health
Primary Subject Heading:	Public health
Secondary Subject Heading:	Global health, Health policy, HIV/AIDS
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, HIV & AIDS < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **How soon should patients be eligible for differentiated service delivery models for antiretroviral**
4 **treatment? Evidence from a retrospective cohort study in Zambia**

5
6
7 3 **Short title: Outcomes of early DSD enrolment**

8
9 4 Lise Jamieson^{1,2}, Sydney Rosen^{1,3*}, Bevis Phiri⁴, Anna Grimsrud⁵, Muya Mwansa⁶, Hilda
10
11 5 Shakwelele⁴, Prudence Haimbe⁴, Mpande M Mwenechanya⁷, Priscilla Lumano-Mulenga⁶, Innocent
12
13 6 Chiboma⁶, Brooke E Nichols^{1,2,3}

14
15
16 7
17
18 8 ¹Health Economics and Epidemiology Research Office (HE²RO), Department of Internal Medicine, Faculty of
19
20 9 Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

21
22 10 ²Department of Medical Microbiology, Amsterdam University Medical Centre, Amsterdam, the Netherlands

23
24 11 ³Department of Global Health, Boston University School of Public Health, Boston, MA, USA

25
26 12 ⁴Clinton Health Access Initiative, Lusaka, Zambia

27
28 13 ⁵IAS - International AIDS Society, Cape Town, South Africa

29
30 14 ⁶Ministry of Health, Lusaka, Zambia

31
32 15 ⁷The Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

33
34
35 16
36
37 17
38 18 *Corresponding author: Sydney Rosen (sbrosen@bu.edu); Department of Global Health, Boston

39
40 19 University School of Public Health, 801 Massachusetts Avenue, Boston, MA, USA. Tel: +1 857-207-
41
42 20 7909

43
44 21
45
46 22 **Keywords:** differentiated service delivery (DSD) models, HIV, antiretroviral treatment, retention in
47
48 23 care, differentiated service delivery guidelines, Zambia

49
50 24
51
52 25 **Word count:**

53
54 26 Abstract: 300/300

55
56 27 Manuscript: 2,719/5,000
57
58
59
60

1
2
3 28 **ABSTRACT**
4

5 29 **Objectives:** Patient attrition is high the first six months after antiretroviral therapy (ART) initiation.
6
7 30 Patients with <6 months ART are systematically excluded from most differentiated service delivery
8
9 31 (DSD) models, which are intended to support retention. Despite DSD eligibility criteria requiring ≥ 6
10
11 32 months on ART, some patients enroll earlier. We compared loss to follow-up (LTFU) between patients
12
13 33 enrolling in DSD models early to those enrolled according to guidelines, assessing whether the ART
14
15 34 experience eligibility criterion is necessary.

16 35
16 36 **Setting:** In a retrospective cohort study using routinely-collected electronic medical record data in
17
18 37 Zambia, we assessed adults (≥ 15 years) who initiated ART between 01/01/2019 and 31/12/2020,
19
20 38 evaluating LTFU (>30 days late for scheduled visit) at 18 months for “early enrollers” (DSD enrolment
21
22 39 after <6 months on ART) and “established enrollers” (DSD enrolment after ≥ 6 months on ART). We
23
24 40 used a log-binomial model to compare LTFU risk, adjusting for age, sex, location, ART refill interval,
25
26 41 DSD model.

27 42
27 43 **Participants:** For 6,340 early enrollers and 25,857 established enrollers there were no differences in
28
29 44 sex (61% female), age (median 37 years), or location (65% urban). ART refill intervals were longer for
30
31 45 established vs early enrollers (72% vs 55% were given 4–6-month refills).

32 46
33
34 47 **Results:** LTFU at 18 months was 3% (192/6,340) for early enrollers and 5% (24,646/25,857) for
35
36 48 established enrollers. Early enrollers were 41% less likely to be LTFU than established patients
37
38 49 (adjusted risk ratio [95% confidence interval] 0.59 [0.50-0.68]).

39 50
40 51 **Conclusions:** Patients enrolled in DSD after <6 months’ ART were more likely to be retained than
41
42 52 patients established on ART prior to DSD enrolment. A limitation is that early enrollers may have been
43
44 53 selected for DSD due to providers’ and patients’ expectations about future retention. Offering DSD
45
46 54 models to ART patients soon after ART initiation may help address high attrition during the early
47
48 55 treatment period.
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTHS AND LIMITATIONS

- Our analysis utilized data from Zambia's national electronic medical record system, with records from the entire national HIV treatment cohort over four years (2018-2021) in all ten provinces.
- We report observed outcomes for more than 6,000 antiretroviral treatment (ART) clients who enrolled in differentiated service delivery (DSD) models after less than six months' experience on ART.
- Results reflect large-scale, routine program implementation, rather than clinical trial settings.
- A key limitation is the assumption that patients who were enrolled in DSD models after less than 6 months on ART were selected based on an expectation of good future adherence.
- A further limitation is the potential bias if facilities with better-than-average retention rates were more likely to allow early DSD model enrollment; results may reflect differences in the quality of services as opposed to the relationship between duration on ART before DSD enrollment and retention in care.

72 INTRODUCTION

73 A critical step toward achieving universal coverage of antiretroviral therapy (ART) for HIV is to support
74 lifelong patient retention in ART programmes. Data from sub-Saharan Africa (SSA), where some 70%
75 of the world's ART patients reside, continue to indicate insufficient retention on ART,¹ with about a
76 fifth of all patients lost to care five years after treatment initiation.² A patient's first six months after
77 initiation are a high risk period for attrition: a Zambian study showed rates of loss to follow-up to be
78 four-fold higher in the first six months of ART treatment compared to the period between six months
79 and 3.5 years thereafter.³

80
81 Since 2016, the World Health Organization (WHO) has recommended differentiated service delivery
82 (DSD) for HIV treatment.⁴ DSD models such as facility-based individual "fast track" medication pickup
83 and community-based ART refills can increase access and remove barriers to care by adjusting the
84 cadre of provider, location of service delivery, frequency of interactions with the healthcare system,
85 and/or types of services offered to support long-term retention of people established on HIV treatment.⁵
86 A recent systematic review reporting on outcomes of patients in DSD models in SSA found that
87 retention in care of those in DSD models was generally within 5% of that for conventional care.⁶ In
88 Zambia, several DSD models have shown to have similar rates of retention as conventional care 12
89 months after DSD model entry.^{7,8} The INTERVAL trial, a cluster-randomized, non-inferiority trial
90 conducted in Malawi and Zambia, found that 6-month ART dispensing was non-inferior in terms of 12-
91 month retention, compared to standard of care.⁸ DSD models have consistently been found to save
92 substantial time and money for patients themselves, and satisfaction with the models among both
93 providers and patients has been high.⁸⁻¹⁰

94
95 A major limitation to the scale-up of DSD models to date has been eligibility criteria that limit
96 enrollment to patients who are "stable" or "established on treatment, which is defined as patients who:
97 i) are on first-line ART regimens; ii) have been on ART for at least 6 or 12 months; and iii) have a
98 recent, documented suppressed viral load.^{8,11-13} Until April 2021, the WHO's definition of "established"
99 included at least 12 months of ART experience; new guidelines require at least 6 months on ART for

1
2
3 100 DSD model eligibility¹⁴. Patients who are newly initiated on ART are thus systematically excluded
4
5 101 from stable-patient-specific DSD models and from the benefits they offer. In the previously cited
6
7 102 INTERVAL trial in Malawi and Zambia, 10% of all patients were excluded due to having initiated ART
8
9 103 less than 6 months prior.¹⁵ For patients not eligible for DSD models, guidelines typically require
10
11 104 frequent visits to the healthcare facility and medication dispensing intervals of no more than 3 months.¹⁶
12
13 105 In Zambia, all care is differentiated and dependent on the needs of the patient,¹¹ but currently there is
14
15 106 no evidence on the outcomes of patients with <6 months ART experience who enroll into DSD models
16
17 107 that are typically reserved for stable patients.
18
19
20 108

21
22 109 Despite existing guidelines limiting DSD eligibility based on time on ART, in practice patients who do
23
24 110 not meet guideline-recommended criteria are sometimes enrolled in DSD models for stable patients,
25
26 111 due to provider decision, error or patient request. To understand how such patients who are referred
27
28 112 early to DSD models fare when participating in DSD models designed for those established on
29
30 113 treatment, we analyzed routinely collected medical record data from Zambia to compare rates of
31
32 114 retention among patients enrolled into DSD models earlier than guidelines recommend with retention
33
34 115 among those who met all eligibility criteria.
35
36
37 116

38 39 117 **METHODS**

40 41 118 **Study population and outcomes**

42
43 119 We conducted a retrospective cohort study with data extracted in October 2021 from SmartCare,
44
45 120 Zambia's national electronic medical record system.¹⁷ We extracted data for patients, aged 15 years or
46
47 121 older, reported to have initiated ART between January 2019 and December 2020 at any of 692 health
48
49 122 facilities across all 10 provinces. Zambian policy guidelines for this period required patients to be stable
50
51 123 on ART before they are considered for DSD enrolment, with stability defined in the 2018 consolidated
52
53 124 ART guidelines^{11,12} as on ART for at least six months.
54
55
56
57 125
58
59
60

1
2
3 126 We defined patients who enrolled into a DSD model with <6 months of ART as “early enrollers”, while
4
5 127 a comparison group of patients who enrolled into a DSD model with ≥ 6 months of ART as “established
6
7 128 enrollers”. Patients on second-line ART (defined as those dispensed protease inhibitors such as
8
9 129 lopinavir, atazanavir or ritonavir) were excluded from this analysis, as they are already known to be at
10
11 130 high risk of attrition.^{18,19} For both early and established enrollers, we assessed loss to follow-up (LTFU)
12
13 131 at 18 months post-ART initiation, with LTFU defined as patients who were reported as “lost to follow-
14
15 132 up” or “inactive” in the SmartCare database between 15 and 21 months after ART initiation date.
16
17 133 “Inactive” was defined as having missed a scheduled visit by more than 30 days. Rates of LTFU were
18
19 134 calculated for early and established enrollers and stratified by DSD model type and ART dispensing
20
21 135 duration. DSD models, which had multiple names in the SmartCare database, were grouped into the
22
23 136 following categories: 1) adherence groups (community adherence groups, rural/urban adherence
24
25 137 groups); 2) extended clinic hours (DSD models designed for clinic access before/after hours or
26
27 138 weekends, including scholar models); 3) fast-track (procedures to accelerate dispensing at clinics); 4)
28
29 139 home ART delivery; 5) multi-month dispensing (MMD); and 6) community pick-up point (central
30
31 140 dispensing units, community retail pharmacies, community ART distribution points, health posts,
32
33 141 mobile ART distribution models) (Table 1). These six DSD models were defined for our analysis to be
34
35 142 mutually exclusive – patients could only be enrolled in a single model.
36
37
38
39 143

40
41 144 **Table 1. Differentiated service delivery (DSD) models for HIV treatment in use in Zambia**
42
43 145 **during the study period**

Category	Model(s) in category	Description
1. Adherence groups	Community adherence groups	Patient groups, consisting of ± 6 members, meeting at an agreed time every 1-3 months. The groups are managed by the patients themselves, and usually meet outside of the health facility. Members collect ART at clinical appoints for other members in a rotating fashion. ⁷
	Rural and urban adherence groups/clubs	Patient groups, consisting of 20-30 members, meeting at an agreed time every 2-3 months. Groups are often facilitated by the same health care worker or facility-based volunteer, also providing pre-packaged ART. ⁷

Category	Model(s) in category	Description
2. Community pick-up point	Central dispensing units	A centralized model for ART distribution, where medication is packed at a centrally located hub and distributed to patients at multiple approved pick-up points. Clinic visits occur every 6 months at the health facility. ¹¹
	Community ART distribution points, community retail pharmacies, health posts	ART refills are provided to patients outside of health facilities, e.g. schools, churches, community centres, community retail pharmacies and health posts. ¹¹
	Mobile ART distribution models	A clinical outreach team linked to a facility does 3-monthly clinical assessments at community distribution points. This model is usually used for hard-to-reach areas. ¹¹
3. Extended clinic hours	Before/after-hours models, weekend models, scholar models	These models allow patients to have a clinical visit and collect their ART outside the conventional operation times at the facility (early mornings, evenings and over weekends). These are beneficial to patients with competing priorities (e.g. school or employment).
4. Fast-track	Fast-track	A model that typically involves a separate, shorter queue to dispense ART to stable patients, allowing for a quick patient visit when a clinical visit is not required. ²⁰
5. Home ART delivery	Home ART delivery	Trained community health workers (CHWs) linked to facilities conduct home visits to deliver ART, conduct health screening, monitor adherence, and refer patients as required. ⁷
6. Multi-month dispensing	Multi-month dispensing	Facility-based model in which the primary goal is to dispense medications for more than one month (usually 6 months). Dispensing is typically done during a clinical facility-based visit.

146

147 Statistical analysis

148 We described the demographics of our study population using descriptive statistics. We compared loss
 149 to follow-up risk between early enrollers and established enrollers and Wilson's score interval was used
 150 to calculate 95% confidence intervals around proportions. We used a log-binomial regression to
 151 calculate risk ratios for loss to follow-up, adjusting for age, sex, urban/rural status, DSD model type
 152 and ART dispensing duration. Analyses were also stratified by DSD model type and ART dispensing

153 duration. Further, we also conducted an age-stratified analysis and a sub-analysis restricted to facilities
 154 with a higher proportion of early enrollers, with results shown in the supplementary material.

155

156 Patient and public involvement

157 Patients and the public were not involved in the design and conduct of this research.

158

159 RESULTS

160 Study populations

161 The full SmartCare data set included 1,520,125 unique patients on ART over 2018-2021, of whom
 162 32,197 had enrolled into a DSD model after ART initiation and had an 18-month outcome reported
 163 within the 15-to-21-month window (Figure 1). Of these, 6,340 patients were reported to have been
 164 enrolled in DSD models <6 months after ART initiation during the study period (early enrollers). The
 165 remaining 25,857 patients comprised the comparison group of established enrollers. For early enrollers,
 166 median time enrolled in a DSD model at the time of outcome evaluation was 14.7 months (IQR 13.0-
 167 16.5); majority (81%, n=20,856) of established enrollers were on DSD models at outcome evaluation
 168 at a median of 5.8 months (interquartile range (IQR) 2.9-8.9) (Table 2). Early enrollers and established
 169 enrollers were similar with respect to age, sex and urban/rural location. Across both groups, the median
 170 age was 37 years (IQR 29 – 44), a majority (61%, 19,580/32,197) were female and most patients resided
 171 in urban settings (64%, n=20,618).

172 **Table 2. Demographics of patients enrolled in differentiated service delivery models**

Variable		Early enrollers of DSD models (N=6,340)	Established enrollers of DSD models (N=25,857)
Age in years, median (IQR)		36 (29-44)	37 (29-44)
Age group	15-24	727 (11%)	2,589 (10%)
	25-34	2,069 (33%)	8,346 (32%)
	35-49	2,658 (42%)	11,424 (44%)
	50+	885 (14%)	3,487 (13%)
Sex	Female	3,914 (62%)	15,666 (61%)
	Male	2,426 (38%)	10,191 (39%)
Location	Rural	2,501 (39%)	9,078 (35%)
	Urban	3,839 (61%)	16,779 (65%)
Year of ART	2019	2,897 (46%)	17,346 (67%)

Variable		Early enrollers of DSD models (N=6,340)	Established enrollers of DSD models (N=25,857)
initiation	2020	3,443 (54%)	8,511 (33%)
DSD type	Adherence groups	149 (2%)	508 (2%)
	Community pickup points	671 (11%)	1,461 (6%)
	Extended clinic hours	85 (1%)	97 (<1%)
	Fast-track	979 (15%)	6,266 (24%)
	Home ART delivery	355 (6%)	973 (4%)
	Multi-month dispensing	4,101 (65%)	16,552 (64%)
ART months dispensed	<2 months	636 (10%)	1,476 (6%)
	3 months	2,197 (35%)	5,688 (22%)
	4-6 months	3,507 (55%)	18,679 (72%)
Outcome Year	2020	2,863 (45%)	17,283 (67%)
	2021	3,477 (55%)	8,574 (33%)
Months on ART at outcome, median (IQR)		17.9 (16.4-19.5)	18.4 (16.7-19.8)
On DSD at outcome	Yes	6,340 (100%)	20,856 (81%)
	No	0 (0%)	5,001 (19%)
Months on DSD at outcome, median (IQR)		14.7 (13.0-16.5)	5.8 (2.9-8.9)
Patient outcomes by 18 months after ART initiation	On treatment	6,133 (97%)	24,646 (95%)
	Died	11 (<1%)	31 (<1%)
	Lost to follow-up	192 (3%)	1,169 (5%)
	Stopped ART	4 (<1%)	10 (<1%)
	Stopped DSD	0 (0%)	1 (<1%)

173

174 Most patients were enrolled in either multi-month dispensing DSD models (65% [n=4,101] of early
 175 enrollers and 64% [n=16,552] of established enrollers) or fast-track (15% [n=979] of early enrollers
 176 and 24% [n=6,266] of established enrollers) (Table 1). Amongst early enrollers, around half (55%,
 177 n=3,477) were dispensed 4-6 months of ART at their most recent ART pickup, 35% (n=2,197) were
 178 dispensed 3 months of ART, and 10% (n=636) were dispensed <2 months of ART. Established enrollers
 179 had slightly longer dispensing intervals with 72% (n=18,679) dispensed 4-6 months of ART, 22%
 180 (n=5,688) dispensed 3 months of ART, and 6% (n=1,476) dispensed <2 months of ART (Table 1).

181

182 Outcomes

183 Early enrollers had a slightly lower rate of loss to follow-up (3.0% [95% confidence interval (CI) 2.6%-
 184 3.5%]) compared to the established enrollers (4.5% [4.3%-4.8%]) (Table 3). Early enrollers experienced
 185 similar or lower loss to follow-up rates than established enrollers across nearly all differentiated models
 186 of care. The exception was extended clinic hours: early enrollers enrolled in the extended clinic hours

187 model had a similar rate of loss to follow-up as established enrollers (10.6%; [5.7%-18.9%] vs. 8.2%
 188 [4.2%-15.4%], respectively). Across both early and established enrollers, longer dispensing periods
 189 were associated with lower rates of loss to follow-up, which increased from 2.5%-3.8% for 4-6-month
 190 dispensing to 3.5%-5.3% for 3-month dispensing to 4.1%-10.6% for <2-month dispensing (Table 3).
 191 Early enrollers with <2 months dispensing had a lower rate of loss to follow-up than did established
 192 enrollers (4.1%; [2.8%-5.9%] vs. 10.6% [9.1%-12.2%]).

194 **Table 3. Relative risk of loss to follow-up at 18 months post-ART initiation for early enrollers of**
 195 **differentiated service delivery (DSD) models**

	Proportion of patients lost to follow-up at 18 months, % (95% CI) [n/N]		Unadjusted risk ratio (95% CI)	Adjusted risk ratio* (95% CI)
	Early enrollers	Established enrollers		
All patients	3.0% (2.6% - 3.5%) [192/6,340]	4.5% (4.3% - 4.8%) [1,169/25,857]	0.67 (0.57-0.78)	0.59 (0.50-0.68)
Stratification: DSD model				
Adherence groups	2.7% (1% - 6.7%) [4/149]	3.1% (1.9% - 5.1%) [16/508]	0.85 (0.25-2.29)	0.79 (0.23-2.12)
Community pickup points	4.5% (3.1% - 6.3%) [30/671]	3.3% (2.5% - 4.3%) [48/1,461]	1.36 (0.86-2.12)	1.30 (0.81-2.03)
Extended clinic hours	10.6% (5.7% - 18.9%) [9/85]	8.2% (4.2% - 15.4%) [8/97]	1.28 (0.51-3.27)	1.19 (0.43-3.34)
Fast track	3.4% (2.4% - 4.7%) [33/979]	3.6% (3.2% - 4.1%) [227/6,266]	0.93 (0.64-1.31)	0.74 (0.50-1.05)
Home ART delivery	1.4% (0.6% - 3.3%) [5/355]	6.3% (4.9% - 8%) [61/973]	0.22 (0.08-0.50)	0.18 (0.06-0.41)
Multi-month dispensing	2.7% (2.3% - 3.2%) [111/4,101]	4.9% (4.6% - 5.2%) [809/16,552]	0.55 (0.45-0.67)	0.51 (0.41-0.61)
Stratification: ART dispensing duration				
<2 months	4.1% (2.8% - 5.9%) [26/636]	10.6% (9.1% - 12.2%) [156/1,476]	0.39 (0.25-0.57)	0.40 (0.26-0.59)
3 months	3.5% (2.8% - 4.4%) [77/2,197]	5.3% (4.8% - 5.9%) [303/5,688]	0.66 (0.51-0.84)	0.64 (0.49-0.81)
4-6 months	2.5% (2.1% - 3.1%) [89/3,507]	3.8% (3.5% - 4.1%) [709/18,679]	0.67 (0.54-0.83)	0.67 (0.53-0.82)

*Model adjusted for age, sex, location, ART dispensing duration and DSD model type

198 In an analysis adjusting for age, sex, location, ART dispensing duration, and DSD model type, early
 199 enrollers in all DSD model types and dispensing durations were 41% less likely to be lost to follow-up
 200 than established enrollers (adjusted risk ratio (aRR) 0.59 [0.50-0.68]) (Table 3). The reduced adjusted
 201 risk of being lost to follow-up were similar for patients in adherence groups (aRR 0.79 [0.23-2.12]),
 202 multi-month dispensing (aRR 0.51 [0.41-0.61]), home ART delivery (aRR 0.18 [0.06-0.41]) and fast
 203 track models (aRR 0.74 [0.50-1.05]). Early enrollers had a statistically insignificant increased risk of

1
2
3 204 being lost to follow-up in the community pick-up point (aRR 1.30 [0.81-2.03]) and extended clinic
4
5 205 hours models (aRR 1.19 [0.43-3.34]) compared to the established enrollers.
6

7 206
8

9 207 An age-stratified analysis produced similar results to the main analysis, with early enrollers in each age
10
11 208 group being less likely to be lost to follow-up than established enrollers in the same age group. However,
12
13 209 the effect of earlier enrollment in DSD on reduced loss to follow-up appeared less pronounced in
14
15 210 patients on 4-6 months' ART dispensing for those aged 25 to 49 years (Appendix Figure S1). In
16
17 211 facilities where a larger proportion of all DSD patients enrolled in DSD models early, the trend towards
18
19 212 early enrollers performing better persisted with respect to loss to follow-up compared to outcomes for
20
21 213 established enrollers (Appendix Figure S2).
22
23

24 214

25 215 **DISCUSSION**

26
27 216 In nearly all of sub-Saharan Africa, DSD model eligibility criteria require that patients be on ART for
28
29 217 a minimum of six months (and in some countries a minimum of 12 months) prior to DSD model
30
31 218 enrollment.²¹ We present a novel analysis from Zambia highlighting good outcomes when newly
32
33 219 initiated ART patients (those with less than 6 months' ART experience) are referred early to DSD
34
35 220 models. Those referred early to DSD appear to have good outcomes across different DSD models and
36
37 221 age categories.
38
39

40 222

41
42
43 223 Our data begin to fill in a gap in the evidence base on the validity of time on treatment as an eligibility
44
45 224 criterion for DSD models. Because few if any countries permit DSD model enrollment for new
46
47 225 initiators, little evidence on their experience in DSD models has been available until now. To date, most
48
49 226 reports on DSD outcomes have been limited to people who have spent a significant amount of time on
50
51 227 ART prior to DSD model enrollment. In the previously mentioned INTERVAL trial, for example,
52
53 228 participants had been on ART for a median of roughly five years at DSD model entry, while patients in
54
55 229 a trial of multi-month dispensing in adherence clubs in South Africa had a median duration on ART of
56
57 230 7.3 years at baseline.²²
58
59

60 231

1
2
3 232 While ART patients in Zambia have historically been lost to follow-up at high rates in the first few
4
5 233 months after ART initiation,³ in our DSD patient population this was less likely to be the case. Our
6
7 234 results provide evidence to support the recent revision of WHO guidelines that reduce time on ART
8
9 235 from 12 to six months on treatment as part the definition of “established” on ART.¹⁴ These findings
10
11 236 offer reassurance and evidence to countries that have expanded eligibility as they scale up DSD
12
13 237 models,^{21,23} particularly to support uninterrupted access to HIV treatment during the COVID-19
14
15 238 pandemic, that earlier referral to DSD is possible without compromising patient care. Even if many, or
16
17 239 most, of the patients in our “early enrollment” sample were selected deliberately because they were
18
19 240 considered at low loss to follow-up risk, our results demonstrate that early eligibility for DSD models
20
21 241 should be considered for at least some patients before they reach six months on ART.
22
23
24 242

25
26 243 Loss to follow up at 18 months after ART initiation for early and established enrollers averaged 1-11%
27
28 244 for all six categories of DSD models studied. We did not observe any programmatically important
29
30 245 differences by model or ART experience prior to model enrollment. Where a programmatically
31
32 246 important difference did arise, in contrast, was in dispensing intervals. Regardless of how long a patient
33
34 247 had been on ART at DSD model enrollment, patients who received ≤ 2 months of medications at a time
35
36 248 were more likely to be lost to follow up than patients who received either 3 months or 4-6 months of
37
38 249 medications. This likely reflects providers’ assessments of patients’ ability to remain on treatment
39
40 250 and/or clinical condition. Those regarded as being at higher risk of attrition are asked to come to the
41
42 251 clinic for medication refills more often, so that they can be monitored and supported more closely.
43
44 252 Ironically, difficulty in accessing the clinic may be the very reason that some patients are at high risk
45
46 253 of attrition. For these patients, insisting on shorter refill durations may simply exacerbate whatever
47
48 254 challenges they face.
49
50

51 255
52
53 256 There were several limitations to our analysis. First, we cannot explain why some patients were enrolled
54
55 257 in DSD models before reaching six months on ART. As noted above, we assume that patients with < 6
56
57 258 months on ART in our sample were not offered DSD model enrollment at random. If providers made
58
59 259 accurate clinical decisions about individual patients’ risks of attrition, patients in our “early enrollment”
60

1
2
3 260 cohorts could over-represent patients thought to have low attrition risk. To achieve the results we found,
4
5 261 providers would have had to make these decisions correctly at multiple sites across the entire country.
6
7 262 If this is the case, our data suggest that the healthcare workers responsible for enrolling patients into
8
9 263 DSD models can successfully identify those who will do well with early enrollment. At the same time,
10
11 264 if the early enrollers in our data set do comprise patients at lower risk of loss to follow-up, then our
12
13 265 results likely underestimate the true rate of loss to follow-up that would occur if early DSD enrollment
14
15 266 were to be broadly available, without the benefit of provider selection.
16
17
18 267

19
20 268 A second limitation is that our data set included only patients reported in the electronic medical record
21
22 269 system to have enrolled in a DSD model. It is possible that some patients not in DSD models may be
23
24 270 recorded as enrolled, and some who were enrolled may have been missed. Third, bias could occur if
25
26 271 facilities with better-than-average retention in care were also more likely to allow early DSD model
27
28 272 enrollment. In this case, our results may reflect differences in facility quality, as well as enrollment
29
30 273 timing. An analysis restricted to facilities with >20% early DSD enrolment showed an even lower risk
31
32 274 of loss to follow-up among patients enrolled early into DSD models, however, compared to patients
33
34 275 with >6 months of ART at DSD entry.
35
36
37 276

38
39 277 Despite these limitations, our analysis demonstrates that patients on ART for less than six months who
40
41 278 are enrolled in existing DSD models can be successfully retained in care and may even fare better than
42
43 279 those left in conventional care and only initiate DSD models greater than six months after ART
44
45 280 initiation. It is likely that not all patients are ready for less intensive DSD models in their first half-year
46
47 281 or year on treatment, but some clearly are. Since DSD models have been shown to be beneficial to
48
49 282 patients and in some cases to providers, offering enrollment to newly-initiating ART patients may
50
51 283 improve ART programs in general. Future research should look more closely at which patients can be
52
53 284 enrolled early and which models of care serve these patients best.
54
55
56 285

57
58 286 **CONCLUSION**
59
60

1
2
3 287 Current policy for DSD model eligibility criteria in Zambia, as in other countries, have required a
4
5 288 minimum of 12 months of ART before a patient is considered for DSD enrolment, and more recently,
6
7 289 a minimum of six months of ART. In order to change guidelines to allow DSD enrolment sooner after
8
9 290 ART initiation (i.e., 6 months or less), large-scale observational evidence, implementation research or
10
11 291 trial data demonstrating good patient outcomes among those who enrol in DSD models < six months'
12
13 292 post ART initiation would be required. This analysis therefore provides a critical first step towards the
14
15 293 reassessment of the delayed DSD enrolment policies, and signals that further research needs to be
16
17 294 conducted in other SSA countries to evaluate patient outcomes for early DSD model enrolment.
18
19

20 295 **COMPETING INTERESTS**

21
22
23 296 We declare no competing interests.
24
25

26 297 **AUTHORS' CONTRIBUTIONS**

27
28
29 298 LJ, BN, SR and AG conceptualized the study. BP, HS, PH, MM, PLM, IC curated data for the study.
30
31 299 BP, HS, PH, MMM provided supervision of the study. LJ led data analysis and drafted the paper along
32
33 300 with BN, SR and AG. All authors contributed to data interpretation and critically reviewed a revised
34
35 301 draft of the manuscript. All authors have read and approved the final manuscript.
36
37

38 302 **FUNDING**

39
40
41 303 Funding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to
42
43 304 Boston University. The funder had no role in study design, data collection and analysis, decision to
44
45 305 publish or preparation of the manuscript.
46
47

48 306 **DATA SHARING**

49
50
51 307 The data is owned by the Zambian Ministry of Health and the use of it was approved by the Human
52
53 308 Research Ethics Committee (University of Witwatersrand, Johannesburg, South Africa) and ERES
54
55 309 Converge IRB (Zambia). All relevant data is included in the paper and supplementary material. The full
56
57 310 data are available upon approval from Zambian Ministry of Health and appropriate ethics committees.
58
59
60

1
2
3 311 **ETHICS**
4

5 312 This study protocol was approved by ERES Converge IRB (Zambia), protocol number 2019-Sep-030,
6
7 313 the Human Research Ethics Committee (Medical) of the University of Witwatersrand, protocol number
8
9 314 M190453, and the Boston University IRB H-38823 for the use of data with a waiver of consent.
10

11 315
12

13
14 316
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


317 REFERENCES

- 318 1. *UNAIDS AIDSinfo: People Living with HIV Receiving ART.*; 2020. Accessed June 15, 2021.
319 <https://aidsinfo.unaids.org/>
- 320 2. Haas AD, Zaniewski E, Anderegg N, et al. Retention and mortality on antiretroviral therapy in
321 sub-Saharan Africa: collaborative analyses of HIV treatment programmes. *J Intern AIDS Soc.*
322 2018;21(2):e25084. doi:10.1002/jia2.25084
- 323 3. Schöni-Affolter F, Keiser O, Mwangi A, et al. Estimating Loss to Follow-Up in HIV-Infected
324 Patients on Antiretroviral Therapy: The Effect of the Competing Risk of Death in Zambia and
325 Switzerland. Myer L, ed. *PLoS ONE.* 2011;6(12):e27919. doi:10.1371/journal.pone.0027919
- 326 4. *World Health Organization. Guidelines on HIV Self-Testing and Partner Notification,*
327 *Supplement to Consolidated Guidelines on HIV Testing Services.*; 2016. Accessed November
328 18, 2020. <https://www.who.int/hiv/pub/vct/hiv-self-testing-guidelines/en/>
- 329 5. Duncombe C, Rosenblum S, Hellmann N, et al. Reframing HIV care: putting people at the
330 centre of antiretroviral delivery. *Trop Med Int Health.* 2015;20(4):430-447.
331 doi:10.1111/tmi.12460
- 332 6. Long L, Kuchukhidze S, Pascoe S, et al. Retention in care and viral suppression in differentiated
333 service delivery models for HIV treatment delivery in sub-Saharan Africa: a rapid systematic
334 review. *J Intern AIDS Soc.* 2020;23(11). doi:10.1002/jia2.25640
- 335 7. Nichols BE, Cele R, Jamieson L, et al. Community-based delivery of HIV treatment in Zambia:
336 costs and outcomes. *AIDS.* 2021;35(2):299-306. doi:10.1097/QAD.0000000000002737
- 337 8. Hoffman RM, Moyo C, Balakasi KT, et al. Multimonth dispensing of up to 6 months of
338 antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded,
339 non-inferiority trial. *The Lancet Global Health.* 2021;9(5):e628-e638. doi:10.1016/S2214-
340 109X(21)00039-5
- 341 9. Nichols BE, Cele R, Lekodeba N, et al. Economic evaluation of differentiated service delivery
342 models for HIV treatment in Lesotho: costs to providers and patients. *J Intern AIDS Soc.*
343 2021;24(4). doi:10.1002/jia2.25692
- 344 10. Guthrie T, Muheki C, Greener R, et al. *Costs and Outcomes of Differentiated ART Service*
345 *Delivery in Uganda: Summary of Findings.*; 2020.
346 [https://sites.bu.edu/ambit/files/2021/02/Uganda-EQUIP-Brief-ART-DSDM-cost-outcomes-](https://sites.bu.edu/ambit/files/2021/02/Uganda-EQUIP-Brief-ART-DSDM-cost-outcomes-FINAL-2020.08.24.pdf)
347 [FINAL-2020.08.24.pdf](https://sites.bu.edu/ambit/files/2021/02/Uganda-EQUIP-Brief-ART-DSDM-cost-outcomes-FINAL-2020.08.24.pdf)
- 348 11. *Ministry of Health. Zambia Differentiated Service Delivery Framework.*; 2018.
- 349 12. *Republic of Zambia. Ministry of Health. Zambia Consolidated Guidelines for Treatment and*
350 *Prevention of HIV Infection.*; 2018.
- 351 13. *Republic of Zambia. Ministry of Health. Zambia Consolidated Guidelines for Treatment and*
352 *Prevention of HIV Infection.*; 2020.
- 353 14. *World Health Organization. Updated Recommendations on Service Delivery for the Treatment*
354 *and Care of People Living with HIV.*; 2021.
355 <https://apps.who.int/iris/rest/bitstreams/1344311/retrieve>

- 1
2
3 356 15. Hoffman RM, Balakasi K, Bardon AR, et al. Eligibility for differentiated models of HIV
4 357 treatment service delivery: an estimate from Malawi and Zambia. *AIDS*. 2020;34(3):475-479.
5 358 doi:10.1097/QAD.0000000000002435
6
7 359 16. Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a
8 360 patient's first six months on antiretroviral therapy for HIV: an applied research agenda. *Gates*
9 361 *Open Res*. 2020;4:116. doi:10.12688/gatesopenres.13159.1
10
11 362 17. Gumede-Moyo S, Todd J, Bond V, Mee P, Filteau S. A qualitative inquiry into implementing an
12 363 electronic health record system (SmartCare) for prevention of mother-to-child transmission data
13 364 in Zambia: a retrospective study. *BMJ Open*. 2019;9(9):e030428. doi:10.1136/bmjopen-2019-
14 365 030428
15
16 366 18. Wandeler G, Keiser O, Mulenga L, et al. Tenofovir in Second-Line ART in Zambia and South
17 367 Africa: Collaborative Analysis of Cohort Studies. *JAIDS Journal of Acquired Immune*
18 368 *Deficiency Syndromes*. 2012;61(1):41-48. doi:10.1097/QAI.0b013e3182632540
19
20 369 19. Kebede HK, Mwanri L, Ward P, Gesesew HA. Predictors of lost to follow up from antiretroviral
21 370 therapy among adults in sub-Saharan Africa: a systematic review and meta-analysis. *Infect Dis*
22 371 *Poverty*. 2021;10(1):33. doi:10.1186/s40249-021-00822-7
23
24 372 20. Huber A, Pascoe S, Nichols B, et al. Differentiated Service Delivery Models for HIV Treatment
25 373 in Malawi, South Africa, and Zambia: A Landscape Analysis. *Glob Health Sci Pract*. Published
26 374 online May 10, 2021;ghsp;GHSP-D-20-00532v1. doi:10.9745/GHSP-D-20-00532
27
28 375 21. *Time on ART before Eligibility for DSD for HIV Treatment. Differentiated Service Delivery*.
29 376 International AIDS Society (IAS); 2020.
30 377 [https://differentiatedservicedelivery.org/Portals/0/adam/Content/jcdklT8RzEqirRdlckAjbQ/File/](https://differentiatedservicedelivery.org/Portals/0/adam/Content/jcdklT8RzEqirRdlckAjbQ/File/1-Time%20to%20DSD%20Eligibility%20D5.pdf)
31 378 [1-Time%20to%20DSD%20Eligibility%20D5.pdf](https://differentiatedservicedelivery.org/Portals/0/adam/Content/jcdklT8RzEqirRdlckAjbQ/File/1-Time%20to%20DSD%20Eligibility%20D5.pdf)
32
33 379 22. Cassidy T, Grimsrud A, Keene C, et al. Twenty-four-month outcomes from a cluster-
34 380 randomized controlled trial of extending antiretroviral therapy refills in ART adherence clubs. *J*
35 381 *Int AIDS Soc*. 2020;23(12):e25649. doi:10.1002/jia2.25649
36
37 382 23. Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV treatment in
38 383 sub-Saharan Africa during COVID-19. *J Int AIDS Soc*. 2021;24(6). doi:10.1002/jia2.25704
39
40 384
41
42
43
44 385
45
46
47 386
48
49
50

51 387 **Figure 1: Flow diagram depicting study population**
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Flow diagram depicting study population

157x99mm (300 x 300 DPI)

Supplementary Appendix to:

How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment?

Lise Jamieson^{1,2*}, Sydney Rosen^{1,3}, Bevis Phiri⁴, Anna Grimsrud⁵, Muya Mwansa⁶, Hilda Shakwelele⁴, Prudence Haimbe⁴, Mpande M Mwenechanya⁷, Priscilla Lumano Mulenga⁶, Innocent Chiboma⁶, Brooke E Nichols^{1,2,3*}

¹Health Economics and Epidemiology Research Office (HE²RO), Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ²Department of Medical Microbiology, Amsterdam University Medical Centre, Amsterdam, the Netherlands; ³Department of Global Health, Boston University School of Public Health, Boston, MA, USA; ⁴Clinton Health Access Initiative, Lusaka, Zambia; ⁵International AIDS Society, Cape Town, South Africa; ⁶Ministry of Health, Lusaka, Zambia ⁷The Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

Figure S1. Relative risk of loss to follow-up within 18 months of ART initiation for early enrollers of DSD models (ie. after <6 months of ART), stratified by dispensing period and age group (reference group: established enrollers of DSD models with >6 months of ART at DSD enrolment; analysis adjusted for sex and urban/rural status)





Figure S2. Proportion loss to follow-up by time on ART at DSD entry, limited to N=37 facilities with >20% of DSD patients at each facility classified as “early enrollers”



A potential area of concern was that facilities that had better-than-average retention would be more willing or able to enroll patients into DSD models early and therefore skew the results. We therefore conducted this sub-analysis where we limited the data to those facilities which had substantial proportion of their patients enrolled into DSD models early. Criteria for this analysis limited the data to facilities where: i) $\geq 20\%$ of patients had early enrollers, and ii) at least 100 patients across both groups (early enrollers and established enrollers). 37 facilities across 8 of 10 provinces were selected for this analysis; 73% (n=27) of facilities were in urban areas. This analysis consisted of 7,103 patients: majority (61%, n=4,351) were female, age group distribution was similar to the main analysis (Table 2) (11%, n=784 were 15-24 years; 35%, n=2,488 were 25-34 years; 43%, n=3,028 were 35-49 years; 11%, n=799 were 50+ years), 81% (n=5,731) of patients were in urban settings. Majority (57%, n=4,028) of patients were enrolled into multi-month dispensing, 29% (n=2,058) were in fast-track, 7% (n=484) were in community pick-up points, 5% (n=350) were in home ART delivery, and <2% were in adherence groups (n=112) and extended clinic hours' groups (n=71).

Results show that in this subset of clinics, early enrollers were less likely to be lost to follow-up (3.0% [77/2,543]), compared to established enrollers (4.6% [212/4,560]). A log-binomial regression assessing risk of loss to follow-up, adjusting for age, sex, urban/rural status, and ART dispensing period estimated that, compared to established enrollers, early enrollers were 40% less likely to be lost to follow-up; adjusted risk ratios (aRR) 0.60 (95% CI 0.46-0.78).

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	a, page 1; b, page 2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-7, Table 1
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8, Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	8-9, Table 2
Outcome data	15*	Report numbers of outcome events or summary measures over time	9-10

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10, Table 3
2		(b) Report category boundaries when continuous variables were categorized		
3		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
5	Discussion			
6	Key results	18	Summarise key results with reference to study objectives	11
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-13
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-13
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	13-14
10	Other information			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.